Endocyte, Inc. - Product Pipeline Review - Q2 2011

Global Markets Direct, July 2011, Pages: 53

Endocyte, Inc. – Product Pipeline Review – Q2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Endocyte, Inc. - Product Pipeline Review - Q2 2011” provides data on the Endocyte, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Endocyte, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Endocyte, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Endocyte, Inc. - Brief Endocyte, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Endocyte, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Endocyte, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Endocyte, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Endocyte, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Endocyte, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Endocyte, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Endocyte, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Endocyte, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Endocyte, Inc. Snapshot
Endocyte, Inc. Overview
Key Information
Key Facts
Endocyte, Inc. – Research and Development Overview
Key Therapeutic Areas
Endocyte, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Endocyte, Inc. – Pipeline Products Glance
Endocyte, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Endocyte, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Endocyte, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Endocyte, Inc. – Drug Profiles
EC145
Product Description
Mechanism of Action
R&D Progress
EC145 + Doxil
Product Description
Mechanism of Action
R&D Progress
EC0225
Product Description
Mechanism of Action
R&D Progress
EC0489
Product Description
Mechanism of Action
R&D Progress
EC0482
Product Description
Mechanism of Action
R&D Progress
EC0531
Product Description
Mechanism of Action
R&D Progress
EC0565
Product Description
Mechanism of Action
R&D Progress
EC0746
Product Description
Mechanism of Action
R&D Progress
EC1069
Product Description
Mechanism of Action
R&D Progress
ECO531
Product Description
Mechanism of Action
R&D Progress
EC0845
Product Description
Mechanism of Action
R&D Progress
Endocyte, Inc. – Pipeline Analysis
Endocyte, Inc. – Pipeline Products by Therapeutic Class
Endocyte, Inc. - Pipeline Products By Target
Endocyte, Inc. – Pipeline Products by Route of Administration
Endocyte, Inc. – Pipeline Products by Molecule Type
Endocyte, Inc. – Recent Pipeline Updates
Endocyte, Inc. - Dormant Projects
Endocyte, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
EC17
EC90 + EC17+ GPI-0100 + IL-2 + IFN-alpha
Endocyte, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Endocyte, Inc., Deals Volume Summary, 2004 to YTD 2011
Endocyte, Inc., Deals Summary By Region, 2004 to YTD 2011
Endocyte, Inc., Deals Summary, 2004 to YTD 2011
Endocyte, Inc. Detailed Deal Summary
Venture Financing
Endocyte Secures $26 Million In Series C-4 Round
Endocyte Secures $15 Million In Series C-3 Financing
Endocyte Secures $23 Million In Series C-2 Financing
Endocyte Secures $15 Million In Series C Financing
Endocyte Secures $7.6 Million In Financing
Debt Offering
Endocyte Completes Private Placement Of $15 Million
Licensing Agreements
Endocyte Enters Into Licensing Agreement With R&D-Biopharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Endocyte, Inc. – Pipeline by Therapy Area and Indication, 2011
Endocyte, Inc. – Pipeline by Stage of Development, 2011
Endocyte, Inc. – Monotherapy Products in Pipeline, 2011
Endocyte, Inc. – Combination Treatment Modalities in Pipeline, 2011
Endocyte, Inc. – Phase III, 2011
Endocyte, Inc. - Phase I, 2011
Endocyte, Inc. - Pipeline By Therapeutic Class, 2011
Endocyte, Inc. - Pipeline By Target, 2011
Endocyte, Inc. – Pipeline By Route of Administration, 2011
Endocyte, Inc. – Pipeline By Molecule Type, 2011
Endocyte, Inc. – Recent Pipeline Updates, 2011
Endocyte, Inc. - Dormant Developmental Projects, 2010
Endocyte, Inc. - Discontinued Pipeline Products, 2010
Endocyte, Inc., Other Locations
Endocyte, Inc., Deals Summary, 2004 to YTD 2011
Endocyte, Inc., Deals Summary by Region, 2004 to YTD 2011
Endocyte, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
Endocyte, Inc. – Pipeline by Therapy Area and Indication, 2011
Endocyte, Inc. – Pipeline by Stage of Development, 2011
Endocyte, Inc. – Monotherapy Products in Pipeline, 2011
Endocyte, Inc. – Combination Treatment Modalities in Pipeline, 2011
Endocyte, Inc. – Pipeline By Therapeutic Class, 2011
Endocyte, Inc. - Pipeline By Target, 2011
Endocyte, Inc. – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Scientific Games Corporation - Company Analysis
• Insight into Samsung Electronics' Notebook PC Business Model
• Ixia - Company Analysis
• Analysis of Google Inc
• Dell Inc.
• Tektronix, Inc.